Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 2/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 12/20 | 0.44 |
| ▸ | CLK2 | P49760 | 10/20 | 0.44 |
| ▸ | CLK3 | P49761 | 10/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | WNT1 | P04628 | 2/20 | 0.42 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.42 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | NEK2 | P51955 | 1/20 | 0.41 |
| ▸ | MAPK15 | Q8TD08 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2397747 | 0.94 | CLK2 (0.51) | TTKMAPK8MAPK10DYRK1ACLK2 | |
| SCHEMBL2396969 | 0.91 | CHEK1 (0.42) | TTKMAPK8MAPK10DYRK1ACLK2 | |
| SCHEMBL1558650 | 0.88 | MTOR (0.49) | TTKMAPK8DYRK1ACLK2CLK3 | |
| SCHEMBL2396580 | 0.87 | MAPK10 (0.44) | MAPK10DYRK1ACLK2CLK3DYRK1B | |
| SCHEMBL1557469 | 0.80 | CLK2 (0.51) | DYRK1ACLK2CLK3WNT1 | |
| SCHEMBL1557578 | 0.80 | RAF1 (0.51) | MAPK10DYRK1ACLK2CLK3DYRK1B | |
| SCHEMBL2396769 | 0.78 | MTOR (0.42) | DYRK1ACLK2CLK3WNT1 | |
| SCHEMBL2396806 | 0.78 | CLK2 (0.50) | DYRK1ACLK2CLK3WNT1 | |
| SCHEMBL1557941 | 0.78 | MTOR (0.53) | TTKMAPK8DYRK1ADYRK1BRAF1 | |
| SCHEMBL1559106 | 0.78 | MTOR (0.50) | TTKMAPK8DYRK1ADYRK1BCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212053-A1 | PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS | PROGENICS PHARMACEUTICALS, INC. | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212053-A1 | PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS | PIK3CA, AKT1, PIK3R5 | TTK 294/4885MAPK8 169/4885MAPK10 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.